Trading Biotech Breakthroughs
The latest erectile dysfunction drug is showing promise of working even faster than those already on the market.
Developed by Vivus, the new drug called Avanafil works by inhibiting the PDE5 enzyme, the same as Pfizer's Viagra and Eli Lilly's Cialis. But Vivus said it’s drug acts faster than its rivals.
Considering sales of current erectile dysfunction therapies total more than $3.5 billion a year, what’s the trade?
I think Vivus is a stock to watch, says Pete Najarian. I wouldn’t be a buyer on this news but definitely keep on eye on the firm. They also have a weight loss drug in the pipeline that could deliver.
I’d forget this erectile dysfunction stuff, says Guy Adami. Instead I like Amgen on a pullback.
Got something to to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to email@example.com.
CNBC.com with wires